IVERIC bio Inc
Change company Symbol lookup
Select an option...
ISEE IVERIC bio Inc
IART Integra Lifesciences Holdings Corp
R Ryder System Inc
AAPL Apple Inc
IIM Invesco Value Municipal Income Trust
QQQ Invesco QQQ Trust
VZ Verizon Communications Inc
CHTR Charter Communications Inc
SPB Spectrum Brands Holdings Inc
USB US Bancorp
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development ofl treatments for retinal diseases with unmet medical needs. Its lead asset clinical stage product candidate Zimura, a complement C5 inhibitor. Zimura is targeting diseases include: Geographic Atrophy (GA), intermediate (age-related macular degeneration) AMD, and autosomal recessive Stargardt disease (STGD1). It is also developing preclinical product candidate IC-500, a High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA and potentially other age-related retinal diseases. Its portfolio also includes two preclinical stage gene therapy product candidates, which include IC-100 and IC-200 and several ongoing gene therapy research programs. The Company is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.

Price
Delayed
$13.40
Day's Change
-0.08 (-0.59%)
Bid
--
Ask
--
B/A Size
--
Day's High
13.47
Day's Low
13.16
Volume
(Light)

Today's volume of 506,594 shares is on pace to be much lighter than ISEE's 10-day average volume of 2,109,201 shares.

506,594

Display:

Providers:

UpdateCancel
6 providers
August 10, 2022
Iveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in a panel discussion titled, "Differentiation in Emerging Treatments for GA dAMD -- Perspectives From ISEE," at the H.C. Wainwright 2nd Annual...(BusinessWire)

August 03, 2022
Iveric Bio to Present at the Wedbush PacGrow Healthcare Conference 2022

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, and Keith Westby, Chief Operating Officer, will participate in a fireside chat at the Wedbush PacGrow Healthcare Conference 2022 on Tuesday, August 9...(BusinessWire)

August 02, 2022
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on August 1, 2022, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees. These inducement grants were...(BusinessWire)

July 26, 2022
Iveric Bio Reports Second Quarter 2022 Operational Highlights and Financial Results

--- GATHER2 Patient Retention Continues to Exceed Expectations with a 12-Month Injection Fidelity Rate of 92.5% - --- Agreement for up to $250 Million in Non-dilutive Debt Financing Secured - --- Exclusive License Entered into for Sustained Release...(BusinessWire)

Iveric Bio Announces Agreement for Up to $250 Million in Non-Dilutive Debt Financing with Hercules Capital and Silicon Valley Bank

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that it has entered into a term loan debt financing facility with Hercules Capital, Inc. (NYSE: HTGC) and Silicon Valley Bank providing the Company with total borrowing capacity of up to $250 million...(BusinessWire)

July 21, 2022
Iveric Bio to Report Second Quarter 2022 Financial Results and Host Conference Call on Tuesday, July 26, 2022

IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its second quarter 2022 financial and operating results on Tuesday, July 26, 2022. Following the announcement, the Iveric Bio management team will host a live conference call and...(BusinessWire)

July 16, 2022
Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura(R) at American Society of Retina Specialists Meeting

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that in a post-hoc analysis from the GATHER1 clinical trial, Zimura showed a reduction of geographic atrophy lesion growth, compared to sham, across all distances from the foveal center point. The...(BusinessWire)

July 06, 2022
DelSiTech and Iveric Bio Enter Exclusive Agreement for Development of Sustained Release Zimura(R)

IVERIC bio, Inc. (Nasdaq: ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura(R) (avacincaptad pegol) using DelSiTech's...(PR Newswire)

July 05, 2022
Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura(R)

IVERIC bio, Inc. (Nasdaq: ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura(R) (avacincaptad pegol) using DelSiTech's...(BusinessWire)

July 01, 2022
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on July 1, 2022, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to one newly-hired, non-executive employee. These inducement grants were...(BusinessWire)

June 10, 2022
Iveric Bio Announces Presentation of Post-Hoc Analysis at Macula Society from GATHER1 Clinical Trial of Zimura(R) in Patients with Geographic Atrophy

IVERIC bio, Inc. (Nasdaq: ISEE) announced today a post-hoc analysis from the Zimura(R) (avacincaptad pegol) GATHER1 clinical trial which explored enhanced Optical Coherence Tomography (OCT) image analysis to examine the effect of Zimura on change in...(BusinessWire)

June 02, 2022
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on June 1, 2022, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to eight newly-hired, non-executive employees. These inducement grants were...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.